Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Company Overview

Asterias Biotherapeutics, Inc. was a biotechnology company focused on developing therapies derived from human pluripotent stem cells. Its research programs targeted conditions with significant unmet medical needs, including spinal cord injury, cancer and other serious diseases.

The company’s lead program, AST-OPC1, was an investigational cell therapy designed to produce oligodendrocyte progenitor cells for potential treatment of spinal cord injury. Asterias also developed AST-VAC2, an investigational cancer vaccine based on dendritic cells and intended to stimulate an immune response against cancer cells.

Asterias was headquartered in Menlo Park, California, and conducted its development activities primarily in the United States. In 2019, BioTime, Inc. completed an acquisition of the company’s outstanding shares, after which Asterias ceased operating as an independent publicly traded company. Its former NYSE American ticker was AST.

Key Stats

• Today's Range: $0.0020 to $0.0020
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $2.05
• Volume: 1,000 shs
• Average Volume: 136,653 shs
• Market Capitalization: $111.32 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/28/2017
• Today: 9/25/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:AST
• Previous Symbol: NYSEMKT:AST
• CIK: N/A
• Web: asteriasbiotherapeutics.com
• Phone: +1-510-4563805
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,659,000
• Free Float: N/A
• Market Cap: $111.32 thousand
• Optionable: Not Optionable
• Beta: N/A